ELVN logo

ELVN Enliven Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$46.58
+1.69 (+3.76%)

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a…

Market Cap: $3.43Bwww.enliventherapeutics.com

Price

No data yet.

Social Signal Score

55
5d
—
30d
70
1 mentions
—
60d
48
3 mentions
—
90d
49
6 mentions
—
news: 6

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 0Sell 0Strong Sell 0
Avg price target$76.29+63.8%
Low $70Median $78High $82
Current Consensus

Revenue

$0.00
$0.00
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-1.74
$-1.76–$-1.71
1 analysts
FY2026
$-1.68
$-2.02–$-1.38
8 analysts
FY2027
$-2.03
$-2.44–$-1.82
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Richard A. Fair
Sector
Healthcare
Industry
Biotechnology
Employees
65
Beta
0.24
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
97.83
www.enliventherapeutics.com